ALEC - Alector Inc. Market Capitalization-to-Revenue Ratio
The current P/S multiple demonstrates the share price's dependence on antibody test results, with the value holding at 1.60. Alector, Inc. (ALEC) develops treatments for Parkinson's and Alzheimer's diseases by activating microglia. Development relies on a staff of leading researchers with access to cutting-edge laboratories. Capital stability ensures security during the prolonged wait for clinical data.
Alector, Inc. (ALEC) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Alector, Inc.|ALEC - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient alector.com|ALEC - Company Aggregate Debts|Debts to Book Capitalization Alector Therapeutics|ALEC - Company Long-Term Debt|Company Short-Term Debt Alector|Immediate Liquidity alector.com
- net income and valuation ratios data:
ALEC - Net Profit|Future Profit Alector, Inc.|ALEC - Price to Earnings Ratio|Price to Future Earnings Ratio alector.com|ALEC - PEG Multiple|Company Value to EBITDA Alector Therapeutics|ALEC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Alector|ALEC - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months alector.com|ALEC - Earnings per share growth in current year|Expected net earnings per share growth next year Alector, Inc.
- total revenue and sales volume data:
General company analysis:ALEC Alector Inc.
The P/S ratio compares market capitalization to annual revenue, allowing for an assessment of business value relative to its ability to generate income. By analyzing historical P/S trends, an investor can identify whether an asset is overbought, which is critical for Alector, Inc. (ALEC), as its valuation is based on strong community confidence in its innovative immunotherapy methods for Alzheimer's disease.
Competitors of Alector, Inc.
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Price-to-Revenue Coefficient Harmony Corp|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|PRAX: Price-to-Revenue Ratio|AVXL: P/S Multiple|Price to Sales CeriBell EEG (CBLL)|PRTA (Prothena Biosciences) - P/S Multiple|Market Cap to Revenue annexonbio.com (ANNX)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Inc - Market Cap to Revenue Ratio|P/S Multiple ACIU (AC Immune Corp)|Voyager Corp (VYGR) - Price to Sales|NMRA: Market Cap to Revenue|SCLX - P/S Multiple|Tevogen Bio (TVGN) - Price-to-Revenue Ratio|Alpha Cognition Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Price to Sales Inhibikase Pharma IKT|P/S Multiple SAVA|P/S Multiple assertiotx.com (ASRT)|Price-to-Revenue Ratio Coya Therapeutics COYA|VistaGen Therapeutics, Inc. - Price-to-Revenue Ratio|Ovid Rx - P/S Multiple|Price to Sales Acumen Pharmaceuticals, Inc|CRVO: P/S Multiple|Market Cap to Revenue Alterity Therapeutics Limited|Market Cap to Revenue CLNN|PEPG (PepGen Corp) - Market Cap to Sales Volume|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD - Price to Sales|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Market Capitalization-to-Revenue Ratio GRCE|AIFF: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KLTO (Klotho Neurosciences Inc)|NRSN: P/S Multiple|RVPH - Price-to-Revenue Coefficient|Price-to-Revenue Ratio MetaVia Inc.|Market Cap to Revenue Ratio NRXS (neuraxis.com)|P/S Multiple HSDT|Market Cap to Revenue passagebio.com PASG|Neuphoria Therapeutics - Market Cap to Revenue|Price-to-Revenue Coefficient Minerva (NERV)|Athira Pharma, Inc. - P/S Multiple|ADXN - P/S Multiple|alzamend.com (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics, Inc.) - Price-to-Revenue Ratio|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Price to Sales Pasithea KTTA|P/S Multiple CRGT|Market Cap to Revenue avenuetx.com ATXI|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|CARA: Market Cap to Revenue Ratio|Chromocell Therapeutics Corporation - P/S Multiple|Price to Sales Eliem Therapeutics|ITCI (intracellulartherapies.com) - Market Cap to Revenue|longboardpharma.com (LBPH) - P/S Multiple|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE - Price to Sales|P/S Multiple SNPX (Synaptogenix, Inc.)|P/S Multiple trevena.com TRVN|VIGL - Price-to-Revenue Ratio|WENA: Price-to-Revenue Ratio|CERE: P/S Multiple
